Gee Paul, Burgner David, Gee Waverley, Forbes Angela, Frampton Christopher M A, McCombie Andrew
Emergency Medicine, Christchurch Hospital Te Whata Ora, Christchurch, New Zealand
Department of Surgery and Critical Care, University of Otago, Christchurch School of Medicine, Christchurch, New Zealand.
Arch Dis Child. 2023 Nov;108(11):916-921. doi: 10.1136/archdischild-2023-325667. Epub 2023 Aug 8.
The recent epidemiology of Kawasaki disease (KD) in New Zealand (NZ) is unknown. Our aim was to describe the incidence, seasonal variation, long-term outcomes and mortality for KD in NZ.
Retrospective national database analysis.
New Zealand.
First hospitalisation and deaths diagnosed with KD.
Data were extracted for all hospital admissions in NZ coded as KD (International Classification of Diseases (ICD)-9 and ICD-10) from the National Minimum Dataset 1 January 2000 to 31 December 2017. Age, sex, ethnicity and associated diagnoses were available to review. Intervention rates for immunoglobulin administration were also analysed.
Over the study period, there were 1008 children with initial hospitalisation for KD. The mean age was 39.8 months (SD 37) and 592 (59%) were boys. The annual incidence rate of KD has increased from 12.2 to 19.5 per 100 000 children <5 years old (0.46 case increase per year; 95% CI 0.09 to 0.83). Children of Asian and Pacific Island ethnicities had the highest incidence (51.2 and 26.1/100 000, respectively). The highest growth in incidence was among East Asian children. The case mortality rate was low (12 of 1008, 1.2%); however, Māori were over-represented (6 of 12 deaths).
There is evidence of increasing KD hospitalisation in NZ, similar to recent studies from Northeast Asia and Australia. KD incidence data were available for retrospective review from a national database, but data on complications and outcomes were incomplete. Notification for KD and an active national surveillance system are recommended to improve care. Future work should focus on factors contributing to poorer outcomes in Māori.
新西兰川崎病(KD)的近期流行病学情况尚不清楚。我们的目的是描述新西兰KD的发病率、季节变化、长期预后和死亡率。
全国性回顾性数据库分析。
新西兰。
首次因KD住院及死亡病例。
从2000年1月1日至2017年12月31日的国家最低数据集里提取新西兰所有编码为KD(国际疾病分类(ICD)-9和ICD-10)的住院病例数据。可查阅年龄、性别、种族和相关诊断信息。还分析了免疫球蛋白的使用干预率。
在研究期间,有1008名儿童首次因KD住院。平均年龄为39.8个月(标准差37),592名(59%)为男孩。<5岁儿童中,KD的年发病率从每10万人12.2例增至19.5例(每年增加0.46例;95%置信区间0.09至0.83)。亚洲和太平洋岛民种族的儿童发病率最高(分别为每10万人51.2例和26.1例)。发病率增长最高的是东亚儿童。病例死亡率较低(1008例中有12例,1.2%);然而,毛利人所占比例过高(12例死亡中有6例)。
有证据表明新西兰因KD住院的人数在增加,这与最近来自东北亚和澳大利亚的研究结果相似。可从国家数据库回顾性查阅KD发病率数据,但并发症和预后数据不完整。建议对KD进行通报并建立一个活跃的国家监测系统以改善医疗护理。未来的工作应关注导致毛利人预后较差的因素。